Lenalidomide | 合法藥品大搜索

(Velcade®)、免疫調節劑(immunomodulatory drugs, IMiDs) 如thalidomide (Thado®) 及 lenalidomide (Revlimid®) 的問世，提升了對多發性骨髓瘤之治療反應率及 ... Read More

由 KC Anderson 著作 · 2005 · 被引用 264 次 — First established as agents with antiangiogenic properties, thalidomide and IMiDs inhibit the production of interleukin (IL)-6, which is a growth factor for the ... Read More

由 Y Zou 著作 · 2013 · 被引用 18 次 — In conclusion, lenalidomide seems to be a more potent and less toxic agent than thalidomide in the treatment of patients with multiple myeloma. Further, a direct ... Read More

由 S Vallet 著作 · 2008 · 被引用 120 次 — Thalidomide and its analogue lenalidomide are potent anti-inflammatory, anti-angiogenic and immunomodulatory drugs, successfully used for the treatment of ... Read More

由 J Luo 著作 · 2017 · 被引用 22 次 — Our results agree with the findings of recently published trials suggesting that thalidomide and lenalidomide are equivalent with respect to survival outcomes but ... Read More

由 M Mian 著作 · 2016 · 被引用 13 次 — Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma? Anticancer Res. 2016 Mar;36(3):1059-65. Read More

由 MP Cruz 著作 · 2016 · 被引用 9 次 — Lenalidomide (Revlimid, Celgene) is a thalidomide derivative introduced in 2004 as an immunomodulatory agent for the treatment of various cancers such as ... Read More

Lenalidomide不如thalidomide有周邊神經炎的問題，卻較容易發生骨髓抑制導致貧血、血小板低下與白血球低下。其他常見的副作用包括頭昏、頭痛、失眠、腹瀉、 ... Read More

由 J Luo 著作 · 2017 · 被引用 22 次 — For patients with multiple myeloma, we found that initiating treatment with lenalidomide in the context of routine care had no significant advantage over thalidomide ... Read More

Multiple myeloma[edit]. Lenalidomide is used to treat multiple myeloma. ... It is a more potent molecular analog of thalidomide, which inhibits tumor angiogenesis, ... Read More